LL-37 peptide is a naturally occurring antimicrobial peptide with a wide range of potential therapeutic applications. It is currently being investigated as a potential treatment for a variety of conditions, including infections, inflammatory diseases, cancer, wound healing, and cystic fibrosis.
The known side effects of LL-37 peptide are generally mild and transient. The most common side effects reported in clinical trials to date include:
- Redness and swelling at the site of injection
- Itching
- Burning sensation
- Pain
- Headache
- Fatigue
- Nausea
- Vomiting
These side effects are typically mild and resolve on their own within a few days. In rare cases, more serious side effects have been reported, such as:
- Allergic reactions
- Anaphylaxis
- Kidney damage
- Liver damage
- Lung damage
- Death
The risk of developing serious side effects from LL-37 peptide is thought to be low, but more research is needed to fully understand the long-term safety of LL-37 peptide therapy.
It is important to note that LL-37 peptide is still in the early stages of development as a therapeutic agent. More research is needed to fully understand the side effects and risks of LL-37 peptide therapy.
Here are some additional things to keep in mind about the side effects of LL-37 peptide:
- The side effects of LL-37 peptide may vary depending on the dose, frequency, and route of administration.
- LL-37 peptide may interact with other medications, so it is important to talk to your doctor before starting LL-37 peptide therapy.
- LL-37 peptide is not recommended for pregnant women or women who are breastfeeding.
- LL-37 peptide is not recommended for people with certain medical conditions, such as kidney disease, liver disease, or lung disease.
If you are considering LL-37 peptide therapy, it is important to talk to your doctor about the risks and benefits. Your doctor can help you determine if LL-37 peptide therapy is right for you and can monitor you for any side effects.
